PegBio Co

PegBio Co Earnings Yield

The Earnings Yield of PegBio Co (2565.HK) as of Nov 18, 2026 is -0.90 %. In the previous year, Earnings Yield was -1.23 % — a change of -26.41% (higher).

Earnings Yield

-0.90 %

YoY

-26.41%

Last updated:

Earnings Yield of PegBio Co is 2025 -0.90 % . Earnings Yield of PegBio Co was 2024 -1.23 % . It decreases by -26.41% higher compared to the previous year.

The PegBio Co Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2022
-1.33 CNY
Jan 1, 2023
-1.21 CNY
Jan 1, 2024
-1.23 CNY
Jan 1, 2025
-0.90 CNY
The PegBio Co Earnings Yield history
YEAREarnings YieldYoY
-0.90 %-26.41%
-1.23 %+1.49%
-1.21 %-8.95%
-1.33 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PegBio Co Stock analysis

What does PegBio Co do? PegBio Co., Ltd. generates revenue primarily through the development and commercialization of innovative drugs targeting chronic and metabolic diseases. The company's flagship product, PB-119, is a near-commercialized long-acting GLP-1 receptor agonist designed for treating type 2 diabetes and obesity. Product candidates such as PB-718, PB-1902, PB-722, PB-2301, and PB-2309 are in development for indications including non-alcoholic steatohepatitis, opioid-induced constipation, and congenital hyperinsulinemia. The company focuses on pharmaceutical markets for chronic disease treatment, targeting patients and healthcare providers seeking advanced therapeutic solutions. PegBio's revenue streams are derived from the sale of PB-119 once it reaches commercialization, alongside potential future sales of its pipeline products. The firm targets healthcare systems and medical professionals in China, where it is headquartered, to address high-prevalence conditions like type 2 diabetes and obesity. Its product portfolio addresses unmet medical needs in metabolic disorders, positioning PegBio to capture market share in the growing biotechnology sector. The company's business model centers on developing proprietary drug candidates with strong clinical potential. PB-119, as a near-commercialized asset, is expected to drive initial revenue, while the broader pipeline of products like PB-718 and PB-2301 targets expanding therapeutic areas. PegBio aims to establish itself as a leader in chronic disease therapeutics through a focused approach on metabolic and endocrine conditions. PegBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PegBio Co stock

Earnings Yield of PegBio Co is -0.90 % in 2025.

Earnings Yield of PegBio Co changed from -1.23 % to -0.90 %, representing a -26.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield PegBio Co since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's PegBio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — PegBio Co

All Key Metrics — PegBio Co